The Technical AnalystExchange: ISE Industry: Biotechnology
Malin Corporation plc Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% €5.60
America/New_York / 2 mai 2024 @ 07:19
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 105.78 mill |
| EPS: | 0.390 |
| P/E: | 14.36 |
| Earnings Date: | Feb 28, 2024 |
| SharesOutstanding: | 18.89 mill |
| Avg Daily Volume: | 0.0081 mill |
| RATING 2024-05-02 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Sell | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | n/a | n/a | n/a | |||
| Asset | ||||||
| Debt | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 1.60x |
| Company: PE 14.36 | sector: PE 8.97 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.28x |
| Company: PE 14.36 | industry: PE 51.86 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
€ 5.44 - 5.76 ( +/- 2.84%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | €5.60 (0.00% ) |
| Volume | 0.0302 mill |
| Avg. Vol. | 0.0081 mill |
| % of Avg. Vol | 371.18 % |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For MLC.IR
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
MLC.IR
Malin Corporation plc, through its subsidiaries, operates in the life sciences industry in Ireland and the United States. It offers life-saving cell and gene therapies for patients with high unmet medical need; medicines to address unmet needs in cancer, infection, and autoimmune diseases; and treatment of recurrent vulvovaginal candidiasis, an unmet need in women's health and onychomycosis or fungal nail infection. The company also provides drugs for protein misfolding diseases; and platform to distinguish disease-driving bacteria from the intestinal microbiota, as well as UV-light disinfection technology solutions. In addition, it provides company secretarial services. Malin Corporation plc was incorporated in 2014 and is headquartered in Dublin, Ireland.